LLY

993.81

+1.76%↑

JNJ

224.78

-0.46%↓

ABBV

205.21

-0.98%↓

UNH

368.37

+0.61%↑

AZN

185.24

+2.6%↑

LLY

993.81

+1.76%↑

JNJ

224.78

-0.46%↓

ABBV

205.21

-0.98%↓

UNH

368.37

+0.61%↑

AZN

185.24

+2.6%↑

LLY

993.81

+1.76%↑

JNJ

224.78

-0.46%↓

ABBV

205.21

-0.98%↓

UNH

368.37

+0.61%↑

AZN

185.24

+2.6%↑

LLY

993.81

+1.76%↑

JNJ

224.78

-0.46%↓

ABBV

205.21

-0.98%↓

UNH

368.37

+0.61%↑

AZN

185.24

+2.6%↑

LLY

993.81

+1.76%↑

JNJ

224.78

-0.46%↓

ABBV

205.21

-0.98%↓

UNH

368.37

+0.61%↑

AZN

185.24

+2.6%↑

Home・Aandelen Lijst・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Gesloten

SectorGezondheidszorg

66 2.23

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

64.51

Max

67.24

Belangrijke statistieken
By Trading Economics
Inkomsten	-317M -142M
Verkoop	98M 452M
K/W Sectorgemiddelde	25.027 67.147
Winstmarge	-31.342
Werknemers	423
EBITDA	-3.5M 281M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+40% upside

Dividenden
By Dow Jones
Volgende Winsten	11 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-1.7B 7.6B
Vorige openingsprijs	63.77
Vorige sluitingsprijs	66

Nieuwssentiment

By Acuity

30%

70%

116 / 347 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

60.49 / 70.14 Steun & Weerstand

Halozyme Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 mei 2026, 23:43 UTC

Belangrijke Nieuwsgebeurtenissen

New Zealand's Unemployment Rate Falls in 1Q

5 mei 2026, 23:20 UTC

Populaire aandelen

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5 mei 2026, 21:48 UTC

Winsten

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5 mei 2026, 21:05 UTC

Acquisities, Fusies, Overnames

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6 mei 2026, 00:00 UTC

Marktinformatie

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5 mei 2026, 23:39 UTC

Marktinformatie

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5 mei 2026, 22:26 UTC

Marktinformatie

AMD Data-Center Business Continues to Surge -- Market Talk

5 mei 2026, 22:20 UTC

Marktinformatie

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5 mei 2026, 22:08 UTC

Winsten

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5 mei 2026, 22:07 UTC

Winsten

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mei 2026, 21:48 UTC

Winsten

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5 mei 2026, 21:48 UTC

Winsten

Pan American Silver 1Q Rev $1.2B >PAAS

5 mei 2026, 21:42 UTC

Winsten

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mei 2026, 21:38 UTC

Winsten

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mei 2026, 21:30 UTC

Winsten

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mei 2026, 21:29 UTC

Winsten

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mei 2026, 21:26 UTC

Winsten

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5 mei 2026, 21:25 UTC

Winsten

Alcon Inc. 1Q EPS 39c >ALC.EB

5 mei 2026, 21:25 UTC

Winsten

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5 mei 2026, 21:24 UTC

Winsten

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mei 2026, 21:18 UTC

Winsten

Mistras Backs 2026 Rev $730M-$750M >MG

5 mei 2026, 21:17 UTC

Winsten

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5 mei 2026, 21:15 UTC

Winsten

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5 mei 2026, 21:12 UTC

Winsten

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5 mei 2026, 21:11 UTC

Winsten

SSR Mining 1Q Rev $581.8M >SSRM

5 mei 2026, 21:10 UTC

Winsten

SSR Mining 1Q Adj EPS $1.15 >SSRM

5 mei 2026, 21:10 UTC

Winsten

SSR Mining 1Q EPS $1.16 >SSRM

5 mei 2026, 21:08 UTC

Winsten

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mei 2026, 21:01 UTC

Winsten

Intact Financial 1Q EPS C$4.12 >IFC.T

5 mei 2026, 21:01 UTC

Populaire aandelen

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Peer Vergelijking

Prijswijziging

Halozyme Therapeutics Inc Prognose

Koersdoel

By TipRanks

40% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 90.4 USD 40%

Hoogste 96 USD

Laagste 75 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Halozyme Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Halozyme Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

60.49 / 70.14Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

116 / 347 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.